Pharma: Other News To Note
Monday, October 21, 2013
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said that the review process for the marketing authorization application for Striverdi Respimat in the European Union had been completed successfully.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.